Inagaki Y, Yamamoto N, Chida T, Okamura N, Tanaka M
Department of Microbiology, School of Medicine, Tokyo Medical and Dental University, Japan.
Jpn J Antibiot. 1995 Mar;48(3):368-79.
Following the oral administration of DU-6859a to six healthy male volunteers at 100 mg per dose three times a day for seven consecutive days, the degree of disturbances of fecal microflora and fecal drug concentrations were examined. The total viable count decreased transiently during the administration due to changes in the number of members of the family Bacteroidaceae, the most predominant organisms. The other obligate anaerobes and most aerobes including facultative anaerobes were suppressed markedly by DU-6859a, with an exception of yeasts. Members of the family Enterobacteriaceae and most of anaerobic bacteria were reduced to below the detection limit in all subjects from the 3rd day of administration period to one day after the discontinuation of the drug. Clostridium difficile was detected in one of the volunteers at the end of administration. Side effects, such as mild transient soft stool and mild transient diarrhoea, were observed in five and one volunteers, respectively. During the administration, DU-6859a was detected in feces at high concentrations which correlated well with the decrease of susceptible members of fecal flora as well as their detection rate.
在6名健康男性志愿者连续7天每天3次、每次100mg口服DU - 6859a后,检测了粪便微生物群的紊乱程度和粪便药物浓度。由于最主要的微生物类群拟杆菌科成员数量的变化,给药期间总活菌数短暂下降。DU - 6859a显著抑制了其他专性厌氧菌和包括兼性厌氧菌在内的大多数需氧菌,但酵母除外。从给药期第3天到停药后1天,所有受试者的肠杆菌科成员和大多数厌氧菌数量均降至检测限以下。给药结束时,在1名志愿者中检测到艰难梭菌。分别有5名和1名志愿者观察到轻度短暂性软便和轻度短暂性腹泻等副作用。给药期间,粪便中检测到高浓度的DU - 6859a,这与粪便菌群易感成员数量的减少及其检出率密切相关。